UBS Group AG
- SEC CIK
- 0001610520
- Latest filing
- Aug 13, 2026
CTKB holding history
Cytek Biosciences, Inc. in every 13F filed by UBS Group AG, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
CTKB overviewAll 13F holders of CTKBFull Q2 2026 holdings
- Shares (Q2 2026)
- 88,914
- Value
- $393.9K
- % of portfolio
- <0.1%
- Quarters held
- 18
- Since Q3 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2026 | 88,914 | $393.9K | <0.1% | −97,967−52.4% | Reduced | Holders |
| Q1 2026 | 186,881 | $816.7K | <0.1% | −273,166−59.4% | Reduced | Holders |
| Q4 2025 | 460,047 | $2.32M | <0.1% | −8,642−1.8% | Reduced | Holders |
| Q3 2025 | 468,689 | $1.63M | <0.1% | −163,363−25.8% | Reduced | Holders |
| Q2 2025 | 632,052 | $2.15M | <0.1% | +20,524+3.4% | Added | Holders |
| Q1 2025 | 611,528 | $2.45M | <0.1% | −54,205−8.1% | Reduced | Holders |
| Q4 2024 | 665,733 | $4.32M | <0.1% | +646,789+3,414.2% | Added | Holders |
| Q3 2024 | 18,944 | $105.0K | <0.1% | −60,588−76.2% | Reduced | Holders |
| Q2 2024 | 79,532 | $443.8K | <0.1% | −3,375−4.1% | Reduced | Holders |
| Q1 2024 | 82,907 | $556.3K | <0.1% | +82,885+376,750.0% | Added | Holders |
| Q4 2023 | 22 | $201 | <0.1% | −595−96.4% | Reduced | Holders |
| Q3 2023 | 617 | $3.41K | <0.1% | −231,992−99.7% | Reduced | Holders |
| Q2 2023 | 232,609 | $1.99M | <0.1% | +155,295+200.9% | Added | Holders |
| Q1 2023 | 77,314 | $710.5K | <0.1% | +32,198+71.4% | Added | Holders |
| Q4 2022 | 45,116 | $460.6K | <0.1% | +41,103+1,024.2% | Added | Holders |
| Q3 2022 | 4,013 | $59.0K | <0.1% | +3,950+6,269.8% | Added | Holders |
| Q2 2022 | 63 | $1.00K | <0.1% | +63 | New | Holders |
| Q4 2021 | 0 | $0 | 0.0% | −831−100.0% | Sold out | Holders |
| Q3 2021 | 831 | $18.0K | <0.1% | +831 | New | Holders |